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Abstract
Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from
therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and
PIK3CA genes. We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF
and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced
colorectal cancer. In these samples 119 KRAS codon 12 and 13 mutations had been identified by sequence analysis, 126
tumors were wild-type for KRAS and the analysis failed in 49 of the 294 samples due to poor DNA quality. The two
mutation assays detected 130 KRAS mutations, among which were 3 codon 61 mutations, and in addition 32 PIK3CA, 13
BRAF and 6 NRAS mutations. In 19 tumors a KRAS mutation was found together with a mutation in the PIK3CA gene. One
tumor was mutant for both PIK3CA and BRAF. In summary, the mutations assays identified 161 tumors with a mutation,
120 were wild-type and the analysis failed in 13. The material cost of the 2 mutation assays was calculated to be 8-fold
lower than the cost of sequencing required to obtain the same data. In addition, the mutation assays are less labor
intensive. We conclude that the performance of the two multiplex mutation assays was superior to direct sequencing.
In addition, these assays are cheaper and easier to interpret. The assays may also be of use for selection of patients with
other tumor types.
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Introduction
Recently a number of randomized trials have shown that
treatment of patients with advanced colorectal cancer (CRC) do
not benefit from therapies targeting the epidermal growth factor
receptor (EGFR) when their tumors harbor mutations in the
KRAS, BRAF and PIK3CA genes [1,2,3]. Consequently, KRAS
mutation analysis is a prerequisite for anti-EGFR therapy in
metastasized CRC and only patients with tumors that harbor no
KRAS mutations receive this therapy (European Medicine
Agency – EMEA-H-C-741 and H-C-558 and U.S. Food and
Drug Administration - FDA Application No. (BLA) 125084 and
No. (BLA) 125147). Recent publications suggest that mutations
in BRAF and PIK3CA may also confer resistance to anti-EGFR
therapy, although this is not entirely clear for PIK3CA yet
[3,4,5,6,7,8,9,10]. In addition, mutations in KRAS, BRAF and
PIK3CA are associated with a worse outcome in patients with
colorectal cancer [11,12]. The protein encoded by the NRAS
gene functions in the same pathway as KRAS and mutations in
this gene have been found in 3% of CRC (http://www.sanger.
ac.uk/genetics/CGP/cosmic/). The NRAS gene is highly ex-
pressed in CRC (http://www.oncomine.org), hence it is to be
expected that tumors with an NRAS mutations are resistant to
EGFR targeted therapy.
The above findings suggest that mutation analysis for the
KRAS, NRAS, BRAF and PIK3CA genes should be implemented
in molecular diagnostic laboratories. Together these genes
harbor 22 possible mutation sites distributed over 7 exons.
Mutation analysis by sequencing therefore typically requires 7
individual PCR reactions followed by 14 bi-directional sequence
reactions. We have previously developed a multiplex assay for
the identification of 11 possible point mutations in the gene for
the fibroblast growth factor receptor 3 (FGFR3) [13] and 4
hotspot mutations in PIK3CA [14]. These mutations are a
common phenomenon in primary and recurrent urinary
bladder carcinomas and various skin lesions [15,16,17,18,19].
The FGFR3 mutation assay needs little DNA, has a high
performance rate on DNA isolated from formalin-fixed paraffin
embedded tissue (FFPE DNA) and urine and was found to be
highly reproducible. Bearing this in mind we set out to develop
similar assays for mutations in the KRAS, NRAS, BRAF and
PIK3CA genes. This resulted in two multiplex assays, one for
BRAF and KRAS mutations and one for PIK3CA and NRAS. The
performance of the assays was tested on 294 CRC samples that
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had been sequenced for mutations in KRAS exon 2 and was
found to be superior to sequencing.
Materials and Methods
Patient Characteristics and Ethics Statement
The samples used in the presented study were taken from a
consecutive series of metastasized colon carcinoma cases analyzed
for KRAS mutation status in the course of routine molecular
pathological identification of applicable patients for anti-EGFR
therapy at the Institute of Pathology, Erlangen, Germany. All
participants for mutation analysis gave written informed consent
via the treating physician. Ethical approval for the retrospective
use of paraffin material for the study was given by the ethical
committee of the University Erlangen.
DNA Isolation and Sequence Analysis
Tumor tissue was marked on a hematoxylin-eosin-stained tissue
section by an experienced surgical pathologist (AH). After
deparaffinization and rehydration tumor cells were carefully
microdissected manually from serial sections. DNA was isolated
using the QIAampH DNA FFPE Tissue Kit (QIAGEN, Hilden,
Germany). Quantity and quality of the DNA were controlled using
a spectral photometer (NanoDropH, peQLab, Erlangen, Ger-
many). Exon 2 of KRAS was amplified using PCR primers
published previously [20] and the QIAGENH Multiplex PCR Kit
using 150–200 ng DNA. PCR cycles were as follows: 94uC for
5 min, 35 cycles of 94uC for 1 min, 60uC for 1 min, 72uC for
1 min, followed by an elongation step at 72uC for 10 min.
Sequence analysis in both directions was performed using PCR
primers and the Big DyeH Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA). Products from
sequence reaction were purified using the DyeExH 2.0 Spin Kit
(QIAGEN, Hilden, Germany) and analysed by capillary electro-
phoresis (ABI PRISMH 310 Genetic Analyzer, Applied Biosys-
tems, Foster City, CA, USA). DNA from cell line HCT116
(obtained from ATCC, Middlesex, United Kingdom) containing a
heterozygous G13D mutation was used as a control for each
analysis.
Mutation Assays
Two multiplex PCRs were designed, the first for BRAF exon 15
and KRAS exons 2 and 3 and the second for PIK3CA exons 9 and
20 and NRAS exons 2 and 3. The primers were chosen in such a
way that the single strands of the PCR products contained as little
potential secondary structure as possible in order to facilitate
efficient annealing of the mutation detection probes. Primers and
probes for PIK3CA were derived from Hurst [14]. Primer
sequences for multiplex PCR are given in Supplementary Table
S1. The multiplex PCR was performed in a total volume of 15 ml,
containing 1x PCR buffer, 1.5 mM MgCl2, 0.5 units Go-Taq
DNA polymerase (Promega, Madison, WI), 0.17 mM dNTP’s
(Roche, Basel, Switzerland), 0.3–1 mM primers (Invitrogen,
Carlsbad, CA), 5% glycerol (Fluka, Buchs SG, Switzerland) and
5 ng genomic DNA. Thermal cycling conditions were: 5 minutes
at 95uC, 35 cycles at 95uC for 45 seconds, 55uC for 45 seconds and
72uC for 45 seconds, followed by 10 minutes at 72uC. The PCR
products were treated with 2 units Exonuclease I (ExoI) and 3
units Shrimp Alkaline Phosphatase (SAP) (USB, Cleveland, Ohio
USA). This was followed by a single nucleotide probe extension
assay using a SNaPshot Multiplex kit (Applied Biosystems, Foster
City, CA) and probes designed to anneal to either the forward or
the reverse strand of a PCR product adjacent to the mutation site
of interest. These probes were fitted with T tails of different length
at their 59ends to allow separation of the extension products by
size. The mutation detection reactions were performed in a total
volume of 10 ml, containing 1 ml SAP/ExoI treated PCR product,
2.5 ml SNaPshot Multiplex Ready Reaction mix, 1 x Big Dye
sequencing buffer and 1 ml probe mix. Thermal cycler conditions
were: 35 cycles of 10 seconds at 96uC and 40 seconds at 58.5uC.
The products were treated with 1 unit SAP at 37uC for 60 min
and 72uC for 15 min and analyzed on an automatic sequencer
(ABI PRISM 3130 XL Genetic Analyzer, Applied Biosystems)
with the fluorescent label on the incorporated ddNTP indicating
the presence or absence of a mutation. For analysis of the data
Genescan Analysis Software version 3.7 (Applied Biosystems) was
used. Supplementary Table S2 gives an overview of the probes
used and indicates the peak color that correlates with each
mutation. Contamination may occur when lifting the cover of the
PCR plate after PCR and when material from the PCR reaction is
transferred to another well for sequencing or for the mutation
assay. This risk is the same for sequencing and the mutation assays.
Contamination will result in relatively small mutant peaks because
only a fraction of the PCR reaction will have been transferred to
another well. Because of this, we usually independently verify a
mutation when the mutant peak is lower than 10% of the wild type
peak.
Results
Mutation Detection Assays
The BRAF/KRAS assay is depicted in Figure 1 with the
interrogated codons and nucleotides shown at the bottom. The
colors of the peaks indicate the nature of the specific dideox-
ynucleotide that was added to the mutation detection probe. The
top panel is a wild type control and the three other panels show
examples of mutations. When a mutation is present a different
dideoxynucleotide is incorporated resulting in a peak of a different
color. Because the type of fluorescent label influences separation
through the polymer, mutant and wild type extension products
usually migrate to slightly different positions, further facilitating
identification of mutations. The BRAS/KRAS assay simultaneously
interrogates 10 nucleotides in 3 exons for 22 possible point
mutations. Figure 2 depicts the PIK3CA/NRAS assay for wild type
control DNA and 3 samples containing mutations. This assay is
able to detect 25 possible mutations in 12 nucleotides in 4 exons.
Validation of the Assays
To validate the assays we analyzed DNA samples isolated from
294 CRCs that had already been analyzed for mutations in exon 2
of the KRAS gene. In 281/294 (96%) of the samples the two
mutation assays were successful in establishing a mutant or wild-
type outcome. Mutations were identified in 161/281 (57%) of the
cases and120 samples were wild-type (43%). We then we
performed a second independent mutation analysis on all samples
and observed that the results of the BRAF/KRAS and PIK3CA/
NRAS assays were completely reproducible. We found 130 KRAS,
32 PIK3CA, 13 BRAF and 6 NRAS mutations. Details of the
mutations are given in table 1. Of the 32 PIK3CA mutations 12
were single mutations, 19 occurred together with a KRAS mutation
and 1 with a BRAFmutation. The mutation assays were performed
in a blinded fashion and the results were compared afterwards
with the results of the sequence analysis. There were 14 samples
with discrepant results between sequence analysis for KRAS exon 2
(covering codons 12 and 13) and the BRAF/KRAS mutation assay.
As the latter had already been confirmed by an independent assay,
the 14 samples were resequenced. In 9 cases, the sequence
outcome now appeared identical to the mutation assay result and
KRAS/BRAF/NRAS/PIK3CA Assays
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in 4 cases sequencing was unsuccessful due to poor DNA quality.
In the 1 remaining sample (no. 289) sequencing suggested wild-
type whereas the mutation assay detected a G12V mutation with
the mutant peak being 6% of the wild type peak, suggesting that
the tumor was heterogeneous. Figure 3 depicts a concise overview
of sequence and mutation assay results. A detailed overview of the
results of sequencing and mutation assays is given in Supplemen-
tary Table S3. In this table we also included the relative peak
height of the mutant peaks compared to the wild type peak as
observed in the mutation assays. Note that this is at best semi-
quantitative because of the different absorbances of the fluorescent
labels, however, it gives an indication of the relative proportions of
mutant and wild-type genes. Wild-type peaks in the assays have a
height between 2000–8000. Peaks (mutant) with a peak height of
100 are always visible. Based on this we estimate that sensitivity is
between 1–5%. This correlates well with the sensitivity calculated
from dilution experiments in a similar assay as published
previously [13]. Note that in some samples the mutant KRAS
peaks were much higher than the peaks representing the wild type
allele. We presume that this indicates loss of the wild-type allele.
Figure 1. Assay for BRAF and KRASmutations. Panel A: wild-type control. Panels B–D: examples of BRAF and KRASmutations. Positions of codons
and nucleotides are indicated at the bottom of the figure.
doi:10.1371/journal.pone.0008802.g001
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Costs Comparison
Next we compared the costs of both approaches. We observed
mutations in all 4 genes, hence we assume that future mutation
analysis, be it by sequencing or any other technique, will include
the PIK3CA, NRAS and BRAF genes. We calculated the costs for all
materials and reagents including those associated with the running
of samples on the ABI 3130 XL sequencer. These amounted to J
7.03 for the two mutation assays together and J 59.54 for bi-
directional sequencing of the 7 exons. Details are given in
Supplementary Table S4. Personnel costs are also lower for the
mutation assays compared to sequencing. This is because only 2
PCR reactions have to be performed compared to 7 for
sequencing and only 2 electrophoresis runs need to be performed
compared to 14 for sequence analysis. There is no need to buy
other equipment than that required for sequence analysis. Any
laboratory with PCR machines and a capillary sequencer can
perform these assays. The cost comparison thus indicates that the
mutation assays are less expensive than sequencing.
Discussion
The EGF receptor signals through the RAS-MAPK and PIK3
kinase pathways. Activating mutations in proteins that function
Figure 2. Assay for PIK3CA and NRAS mutations. Panel A: wild-type control. Panels B–D: examples of PIK3CA and NRAS mutations. Positions of
codons and nucleotides are indicated at the bottom of the figure.
doi:10.1371/journal.pone.0008802.g002
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downstream of the EGFR in these signal transduction pathways
renders the cell independent of EGFR signaling. Hence inhibition
of the receptor has no effect. Most other receptor tyrosine kinases
employ the same signaling pathways and therefore the same
mechanism is likely to apply to trastuzumab resistant breast cancer
or gefitinib or erlotinib resistant NSCLC [21]. KRAS mutation
analysis is now standard for selection of patients for EGFR
targeted therapy. Recently, it has been shown that mutations in
the PIK3CA and BRAF genes may also confer resistance to anti-
EGFR therapy although patient numbers are still small
[3,4,6,7,8,22,23]. It is likely that patients with tumors harboring
NRAS mutations will also not benefit from anti-EGFR therapy,
however, this remains to be proven which is also the case for
mutations in the NRAS gene. Once this has been established,
mutation analysis for the selection of patients for whom anti-
EGFR therapy will be beneficial presumably has to be extended to
KRAS exon 3, PIK3CA, BRAF and NRAS. Here we presented two
simple assays that together screen 22 mutation sites in the KRAS,
BRAF, PIK3CA and NRAS oncogenes. When we dismiss the failed
samples, KRAS exon 2 mutations were found by sequence analysis
in 119/245 (49%) of the patients, the mutation assays detected
161/281 (57%) patients with mutant tumors. This suggests that
when both sequencing and mutation analysis are 100% successful,
8% of patients (57 minus 49) would receive anti-EGFR therapy in
vain when only exon 2 of KRAS would have been assayed. In
practice, patients with tumors in which the analysis failed will
receive anti-EGFR therapy, suggesting that efficient mutation
detection is important.
Identification of the mutations in the assays presented here is
more straight forward than with sequencing and the results were
completely reproducible. Sequence analysis failed in 17% of the
samples. This was 4% for the KRAS mutation assay. The DNA
samples used in our analyses were FFPE derived. It is known that
FFPE derived DNA is not always of good quality and this was
indeed the reason for the failed samples. In principle sequencing
and the mutation assays are similar techniques. That the mutation
assay is able to give a result in more samples than sequencing is
probably because the fluorescent signals are distributed over fewer
peaks. In cases with poor DNA quality, this is also immediately
apparent from much lower or even missing peaks. Although not
used in this work, it is possible to repeat the mutation assay with a
single probe when one doubts the result, for instance when the
presumed mutant peak is very small.
For analysis of all the mutations by sequencing one would have
to perform independent PCRs for the 7 exons, followed by 14 bi-
directional sequencing reactions. In the mutation assays two
multiplex PCRs for 3 and 4 exons, respectively, are followed by
two multiplex detection assays and two electrophoresis runs on the
sequencer. Besides being considerably cheaper (J7 compared to
J60), less DNA is needed and the assays are less labor intensive.
We conclude that these assays provide a simple and inexpensive
companion diagnostic for the selection of CRC patients for anti-
EGFR therapy. The assays may also be of use for selection of
patients with ERBB2 positive breast cancer or non-small cell lung
cancer carrying EGFR mutations.
Figure 3. Overview of the resultsobtained by the mutation
assays (A) and by sequence analysis (B) in 294 tumor DNA
samples from patients with advanced colorectal cancer.
doi:10.1371/journal.pone.0008802.g003
Table 1. Mutations identified with the BRAF/KRAS and
PIK3CA/NRAS assays.
Gene Codon No. Total
KRAS
G12A 5
G12C 11
G12D 48
G12S 6
G12V 35
G13D 21
G13R 1
Q61L 2
Q61H 1 130
PIK3CA
E542K 5
E545G 1
E545K 13
H1047R 13 32
BRAF
V600E 13 13
NRAS
G12V 2
Q61L 1
Q61R 3 6
doi:10.1371/journal.pone.0008802.t001
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Supporting Information
Table S1 Primer sequences for multiplex PCR.
Found at: doi:10.1371/journal.pone.0008802.s001 (0.02 MB
XLS)
Table S2 Overview of the probes used and indication of the
peak color that correlates with each mutation.
Found at: doi:10.1371/journal.pone.0008802.s002 (0.02 MB
XLS)
Table S3 Detailed overview of the results of sequencing and
mutation assays.
Found at: doi:10.1371/journal.pone.0008802.s003 (0.06 MB
XLS)
Table S4 Costs: Mutation Assays vs. Sequencing (Bi-directional).
Found at: doi:10.1371/journal.pone.0008802.s004 (0.02 MB
XLS)
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